Diagnostic companies are racing into dementia testing because three factors have converged: a rapidly aging population that will drive demand, new medications that only work when dementia is caught in its earliest stages, and blood tests that can now detect Alzheimer’s pathology years before memory loss appears. For a patient like Margaret Chen, 58, who took a blood test through her primary care doctor in 2024, this shift meant catching early cognitive changes that wouldn’t have shown up on a traditional memory test, opening a path toward treatment options that her mother—diagnosed at 73 with full dementia—never had access to. The commercial opportunity is substantial. The global dementia diagnostics market is projected to reach $8.2 billion by 2030, growing at nearly 13% annually.
But the real driver isn’t just the money—it’s that the landscape of dementia treatment has fundamentally changed. For two decades, dementia care meant symptom management and decline. Now, with drugs like lecanemab showing 35% slowing of cognitive decline in early Alzheimer’s, early detection has become the gateway to treatment rather than just a label. This shift has triggered a race among established diagnostics companies like Quest Diagnostics and LabCorp, specialist biomarker firms like Eli Lilly and Roche, and startups targeting the pre-dementia stage, each competing to own the early-detection space before the market consolidates.
Table of Contents
- Why the Population Boom Creates Urgency for Early Detection
- The Blood Test Revolution and Its Accuracy Limitations
- A Fragmented Marketplace Confuses Doctors and Patients
- How Primary Care Doctors Are Adopting These Tests
- Overdiagnosis, Anxiety, and the Risks of Early Labeling
- Access Gaps and Unequal Distribution of Early Detection
- The Clinical Action Gap After Testing
- Frequently Asked Questions
Why the Population Boom Creates Urgency for Early Detection
The primary driver is straightforward: the population that needs testing is growing while the window for effective intervention is opening. The U.S. population aged 65 and older will nearly double to 73 million by 2050, and an estimated 6.9 million Americans currently live with Alzheimer’s disease, the most common form of dementia. But the real urgency comes from the fact that lecanemab and other disease-modifying therapies in development require patients to be diagnosed at the mild cognitive impairment (MCI) or asymptomatic stage—well before the point where someone would traditionally seek care. Historically, a dementia diagnosis came only when cognitive loss was obvious enough to disrupt daily life. By that point, irreversible neurodegeneration was already advanced.
The new drugs, however, work best when started early, creating a race to identify who needs treatment before symptoms fully emerge. A patient diagnosed with MCI and started on treatment may maintain cognitive function for years, while someone diagnosed after full dementia onset gets limited benefit. This clinical reality has transformed dementia from a late-stage diagnosis to an early-detection problem. The reimbursement environment has started shifting to support this. Medicare began covering certain blood-based biomarker tests for cognitive impairment in 2023, and private insurers have begun following. Without reimbursement, the market remains niche; with it, blood tests become routine in primary care, creating volume at scale.
The Blood Test Revolution and Its Accuracy Limitations
The breakthrough technology enabling this race is the blood test. companies have developed tests that measure tau phosphorylation (p-tau), phosphorylated tau 181 (p-tau181), neurofilament light chain (NfL), and other markers to detect Alzheimer’s pathology in blood with reasonable accuracy. Eli Lilly’s phospho-tau test, for example, shows 90% sensitivity and specificity in detecting amyloid positivity in the brain—meaning it identifies nearly all people with the underlying pathology. But here’s the limitation: a positive blood test does not equal dementia, nor does it guarantee someone will develop dementia.
Someone with positive amyloid and tau markers may remain cognitively normal for years or even indefinitely. A 65-year-old with positive biomarkers but perfect memory poses an ethical question: does early diagnosis of asymptomatic Alzheimer’s pathology improve outcomes, or does it create unnecessary anxiety and lifelong treatment? The studies backing lecanemab enrolled people who already had mild cognitive impairment—not asymptomatic people with biomarkers alone. This distinction matters clinically and commercially. Screening healthy people for asymptomatic Alzheimer’s pathology could massively expand the addressable market for drugs and diagnostic tests, but it also risks medicalizing people who would never have had symptoms. Diagnostic companies are betting that insurance and healthcare systems will embrace earlier and earlier intervention; critics worry about overdiagnosis and turning healthy aging into a disease.
A Fragmented Marketplace Confuses Doctors and Patients
The race to own early detection has created intense competition and complexity. Quest Diagnostics offers the Amyloid Blood Test, LabCorp has its own p-tau panel, Eli Lilly has developed and licensed biomarker tests through partnerships, and Roche offers the elecsys tests through their clinical laboratory division. There’s also a wave of venture-backed startups like C2N Diagnostics offering the PrecivityAD blood test and others, each betting they can establish clinical evidence and insurance coverage before the giants consolidate the space. The competition is driving down costs—blood tests that cost $500 to $1,000 five years ago now run $200 to $400—but it’s also creating fragmentation where primary care doctors face a confusing array of options with slightly different biomarkers and accuracy claims.
One concrete example: in 2024, a 60-year-old with family history of dementia could order an amyloid blood test through their doctor, get results within weeks, but find that the results (positive for amyloid but normal cognition) don’t directly map to any approved treatment or clear clinical pathway. The test answered a question—do you have the pathology?—but didn’t necessarily clarify the next step. Each company is trying to be the first test recommended by primary care doctors, the most widely covered by insurance, or the most integrated into clinical workflows. In some regions, blood tests are routine; in others, they’re still rare or barely known.
How Primary Care Doctors Are Adopting These Tests
Primary care is becoming the battleground for dementia diagnostic adoption. Unlike oncology or neurology, where specialists control the diagnostic pathway, dementia care starts in the primary care office. A family member might ask the doctor, “Should my mother get tested for Alzheimer’s?” or a patient might mention forgetting names. Increasingly, the doctor’s response is: “Let’s get a blood test.” The challenge is knowing who to test. Guidelines from the Alzheimer’s Association suggest cognitive testing using the Montreal Cognitive Assessment or similar tools before moving to biomarker tests, but primary care doctors often don’t have time for formal cognitive assessment.
Some practices are adopting simple screening questionnaires like the MoCA or 30-second cognitive screeners, while others just order the blood test directly. The result is highly variable adoption, with some regions and practices embracing blood tests as routine while others still rely on traditional memory complaints. Medicare’s coverage decision created some standardization: the tests are covered when ordered for patients with cognitive impairment or those being evaluated for cognitive impairment, which means the test should be preceded by cognitive assessment. In practice, convenience drives adoption more than guidelines. A blood test that can be ordered at any lab and reviewed in the primary care office is far easier to scale than referrals to neurologists or memory clinics, which have long wait times.
Overdiagnosis, Anxiety, and the Risks of Early Labeling
A significant downside of the dementia testing race is the potential for overdiagnosis—diagnosing asymptomatic people with biomarker abnormalities and treating them as patients before they have actual disease. If widespread blood screening becomes routine, a 50-year-old with a positive amyloid test but perfect cognition would be labeled as having “preclinical Alzheimer’s disease” and possibly started on a disease-modifying drug. The problem is that we don’t yet know the natural history of asymptomatic biomarker positivity. Some people with positive amyloid and tau live into their 90s with normal cognition.
Starting them on lecanemab—which carries risks including amyloid-related imaging abnormalities (ARIA), including microhemorrhages visible on MRI—means accepting those risks for an outcome (preventing cognitive decline) that may never have happened. This is why many dementia experts have urged caution about screening asymptomatic people, and why regulatory approval for lecanemab includes a requirement that patients have cognitive impairment, not just biomarkers. Diagnostic companies, however, profit from more tests, not from restraint. There’s an inherent incentive to expand the definition of “at risk” and to position earlier testing as better. A patient who reads about blood tests for Alzheimer’s online may request testing even if they have no cognitive concerns, and the anxiety of a positive test in an asymptomatic person often goes unresolved by medical literature that says “you may or may not develop dementia.”.
Access Gaps and Unequal Distribution of Early Detection
Blood tests for dementia are more accessible than traditional cognitive assessment or PET imaging, but cost and insurance coverage remain barriers. An uninsured patient might pay $300 to $500 out of pocket for a blood test; with insurance, they’ll typically pay a copay, but only if the test is covered. Medicare covers the tests, but some private insurers still don’t, and geographic variation in coverage is significant.
This creates a two-tier system. A wealthy patient in an urban area with good insurance can easily access blood tests and specialists; a low-income patient or someone in a rural area with limited insurance options faces delays and out-of-pocket costs. The companies rushing into the market are targeting volume and scale, which tends to benefit urban and insured populations first. Underserved communities—including Black and Hispanic Americans, who carry disproportionate dementia risk—are most likely to be left behind in the initial wave of testing adoption.
The Clinical Action Gap After Testing
Getting a positive blood test is only the beginning. Many patients face unclear next steps. You get results showing amyloid and tau in your blood. Then what? Do you see a neurologist? Start medication? Get an MRI to confirm? There’s often no clear pathway forward.
A patient in a rural area might get a positive blood test from their primary care doctor but face no neurology specialists for 200 miles. Another patient discovers that while insurance covers the blood test, it doesn’t cover the neurologist visit or PET scan needed to confirm the diagnosis, leaving them with knowledge of pathology but no clear diagnosis and no clear treatment decision. Some patients get positive results and never follow up because the next steps are too complicated, too expensive, or too uncertain. For these patients, the blood test created information without creating clinical action.
- —
Frequently Asked Questions
Can a blood test diagnose dementia?
Not exactly. Blood tests detect Alzheimer’s pathology (amyloid and tau) in people who may or may not have cognitive symptoms. If you have cognitive impairment plus positive biomarkers, that’s consistent with Alzheimer’s dementia. If you have positive biomarkers but normal cognition, you have asymptomatic pathology, not dementia.
How accurate are the blood tests?
Blood tests for detecting amyloid and tau show 85–95% sensitivity and specificity when compared to PET imaging or cerebrospinal fluid tests. That’s reasonably accurate, but not perfect. They’re more reliable at detecting pathology than at predicting who will develop cognitive decline.
Does insurance cover dementia blood tests?
Medicare covers blood-based biomarker tests for patients with cognitive impairment or those being evaluated for cognitive impairment. Private insurance coverage varies by state and plan. Without insurance, tests typically cost $300–500 out of pocket.
If a test shows I have Alzheimer’s pathology, should I start treatment?
That depends on whether you have cognitive impairment and on your individual risk tolerance. Lecanemab is approved for mild cognitive impairment or mild dementia, not for asymptomatic biomarker positivity. Your doctor should discuss benefits, risks, and your preferences before any treatment starts.
What happens if I have a family history of dementia but no symptoms—should I get tested?
Family history increases risk, but testing asymptomatic people remains controversial. Some doctors recommend cognitive screening and lifestyle interventions first, then biomarker testing if cognitive symptoms emerge. Others offer testing to asymptomatic people with strong family history. Discuss the pros and cons with your doctor before deciding. —
